Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 5/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | HBB | P68871 | 1/20 | 0.52 |
| ▸ | PYGM | P11217 | 3/20 | 0.52 |
| ▸ | NT5E | P21589 | 1/20 | 0.51 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.51 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.51 |
| ▸ | CD69 | Q07108 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10895353 | 0.90 | LMNA (0.56) | TK2LMNASMN1; SMN2TSHRMAPT | |
| SCHEMBL6536580 | 0.90 | LMNA (0.51) | TK2LMNASMN1; SMN2TSHRMAPT | |
| SCHEMBL7800239 | 0.90 | P2RY6 (0.54) | TK2LMNASMN1; SMN2TSHRMAPT | |
| SCHEMBL18503446 | 0.86 | LMNA (0.47) | TK2LMNASMN1; SMN2TSHRMAPT | |
| SCHEMBL17198346 | 0.85 | P2RY6 (0.46) | TK2LMNASMN1; SMN2TSHRMAPT | |
| SCHEMBL28113579 | 0.84 | LMNA (0.56) | TK2LMNASMN1; SMN2TSHRMAPT | |
| SCHEMBL659077 | 0.84 | LMNA (0.56) | TK2LMNASMN1; SMN2TSHRMAPT | |
| SCHEMBL659076 | 0.84 | LMNA (0.56) | TK2LMNASMN1; SMN2TSHRMAPT | |
| 5-Fluorouridine SCHEMBL17173362 | 0.84 | PYGM (0.70) | TK2LMNASMN1; SMN2TSHRMAPT | |
| 5-Fluorouridine SCHEMBL329381 | 0.84 | PYGM (0.70) | TK2LMNASMN1; SMN2TSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0851866-B1 | THERAPEUTIC COMPOUNDS | OXFORD GLYCOSCIENCES UK LTD (GB) | 2001-08-29 | — | — | EP | claimed |
| EP-0851866-B1 | THERAPEUTIC COMPOUNDS | OXFORD GLYCOSCIENCES UK LTD (GB) | 2001-08-29 | — | — | EP | disclosed |
| US-5945406-A | ANTICANCER AGENTS; TREATMENT FOR METASTATIC LIVER CANCER, FUNGAL INFECTIONS, PSORIASIS; USED IN MANUFACTURE OF DRUGSTO PREVENT CELL DIVISION | OXFORD GLYCOSCIENCES (UK) LTD. (GB) | 1999-08-31 | — | — | US | disclosed |
| EP-0851866-A1 | THERAPEUTIC COMPOUNDS | Oxford GlycoSciences (UK) Limited (GB) | 1998-07-08 | — | — | EP | disclosed |
| WO-1997000882-A1 | THERAPEUTIC COMPOUNDS | OXFORD GLYCOSCIENCES (UK) LIMITED (GB) | 1997-01-09 | — | — | WO | disclosed |